


LTA4H-IN-1

Cat. No.:	HY-137298		
CAS No.:	1799681-85-8		
Molecular Formula:	C ₁₆ H ₁₄ ClFN ₆ O ₃		
Molecular Weight:	392.77		
Target:	Aminopeptidase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (254.60 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.5460 mL	12.7301 mL	25.4602 mL
		5 mM	0.5092 mL	2.5460 mL	5.0920 mL
10 mM		0.2546 mL	1.2730 mL	2.5460 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC ₅₀ of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders ^[1] .
IC ₅₀ & Target	IC50: 2 nM (LTA4H) ^[1]
In Vitro	LTA4H-IN-1 (15 min) inhibits the hydrolysis of 7-amino-4-methylcoumarin (AMC) derivative of Arginine (Arg-AMC) which is catalyzed by LTA4H, with an IC ₅₀ of 2 nM ^[1] .

	LTA4H-IN-1 (30 min) inhibits LTB4 biosynthesis in a human whole blood assay (hWB), with an IC ₅₀ of 167 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	LTA4H-IN-1 (0.3 mg/kg; a single p.o.) inhibits the -43% release of LTB4 compared with vehicle control in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bollbuck B, et, al. Heteroaryl butanoic acid derivatives as leukotriene A4 hydrolase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2015092740A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA